These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22500311)

  • 1. [The "cost-benefit" analysis of new antiepileptic drugs].
    Vlasov PN; Orekhova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(10 Pt 1):39-43. PubMed ID: 22500311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Epilepsy in adults: a costs-of-illness study].
    Vlasov PK; Orekhova NV; Filatova NV; Leonova MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3 Suppl 2):44-7. PubMed ID: 20873473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiepileptics].
    Overweg J
    Ned Tijdschr Geneeskd; 1998 Feb; 142(6):289-93. PubMed ID: 9562728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Social and economic aspects of administration of new antiepileptic drugs].
    Dławichowska E; Owczarek K; Fiszer U
    Neurol Neurochir Pol; 2001; 35(2):245-52. PubMed ID: 11599223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use.
    Cramer JA; Wang ZJ; Chang E; Copher R; Cherepanov D; Broder MS
    Epilepsy Behav; 2015 Mar; 44():40-6. PubMed ID: 25635369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany.
    Strzelczyk A; Haag A; Reese JP; Nickolay T; Oertel WH; Dodel R; Knake S; Rosenow F; Hamer HM
    Epilepsy Behav; 2013 Jun; 27(3):433-8. PubMed ID: 23591262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients.
    Knoester PD; Deckers CL; Termeer EH; Boendermaker AJ; Kotsopoulos IA; de Krom MC; Keyser T; Renier WO; Hekster YA; Severens HL
    Value Health; 2007; 10(3):173-82. PubMed ID: 17532810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of antiepileptic pharmacotherapy in a tertiary referral center in South India: a pharmacoepidemiologic and pharmacoeconomic study.
    Radhakrishnan K; Nayak SD; Kumar SP; Sarma PS
    Epilepsia; 1999 Feb; 40(2):179-85. PubMed ID: 9952264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET).
    Boon P; Dejonghe P; Legros B; Sadzot B; van Rijckevorsel K; Schmedding E
    Seizure; 2008 Jun; 17(4):350-7. PubMed ID: 18203628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis for the use of serum antiepileptic drug level monitoring in children diagnosed with structural-metabolic epilepsy.
    Salih MR; Bahari MB; Shafie AA; Hassali MA; Al-Lela OQ; Abd AY; Ganesan VM
    Epilepsy Res; 2013 Mar; 104(1-2):151-7. PubMed ID: 23103061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quality of life and cost-effect aspects of epilepsy pharmacotherapy of women].
    Iutskova EV; Avakian GN; Tatarinova MIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(1):52-5. PubMed ID: 17310798
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of costs of epilepsy using an electronic practice management software in Germany.
    Noda AH; Hermsen A; Berkenfeld R; Dennig D; Endrass G; Kaltofen J; Safavi A; Wiehler S; Carl G; Meier U; Elger CE; Menzler K; Knake S; Rosenow F; Strzelczyk A
    Seizure; 2015 Mar; 26():49-55. PubMed ID: 25799902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit analysis, cost-effectiveness analysis, and impact of antiepileptic drugs on the risk of fracture in patients with epilepsy: A nationwide cohort study.
    Cheng HH; Kung PT; Wang BR; Chiu LT; Tsai WC
    Epilepsy Behav; 2020 Feb; 103(Pt A):106851. PubMed ID: 31889639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of add-on lamotrigine therapy in clinical practice.
    Knoester PD; Boendermaker AJ; Egberts AC; Hekster YA; Keyser A; Severens JL; Renier WO; Deckers CL
    Epilepsy Res; 2005 Dec; 67(3):143-51. PubMed ID: 16288850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy.
    Ettinger AB; Manjunath R; Candrilli SD; Davis KL
    Epilepsy Behav; 2009 Feb; 14(2):324-9. PubMed ID: 19028602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
    Davis KL; Candrilli SD; Edin HM
    Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar response to anti-epileptic medications among epileptic siblings.
    Sonmezturk HH; Arain AM; Paolicchi JM; Abou-Khalil BW
    Epilepsy Res; 2012 Feb; 98(2-3):187-93. PubMed ID: 22030126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of anti-epileptic drugs as adjunctive therapy for refractory epilepsy.
    Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):309-15. PubMed ID: 20545595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiepileptic Drug Titration and Related Health Care Resource Use and Costs.
    Fishman J; Kalilani L; Song Y; Swallow E; Wild I
    J Manag Care Spec Pharm; 2018 Sep; 24(9):929-938. PubMed ID: 29486142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of epilepsy surgery in a cohort of patients with medically intractable partial epilepsy--preliminary results].
    Picot MC; Neveu D; Kahane P; Crespel A; Gélisse P; Hirsch E; Derambure P; Dupont S; Landré E; Chassoux F; Valton L; Vignal JP; Marchal C; Rougier A; Lamy C; Semah F; Biraben A; Arzimanoglou A; Petit J; Thomas P; Dujols P; Ryvlin P
    Rev Neurol (Paris); 2004 Jun; 160 Spec No 1():5S354-67. PubMed ID: 15331984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.